RxDoctor Payments Data

Tanveer Sobhan, MD

Psychiatry · Tamarac, FLNPI 1780726836

Payments from drug & device makers

$758in general payments, 2019–2025

Across 40 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$214
  • Otsuka America Pharmaceutical, Inc.$178
  • Teva Pharmaceuticals USA, Inc.$111
  • Vanda Pharmaceuticals Inc.$91
  • AbbVie$24
  • Livanova USA, Inc.$23
  • plus $117 from 7 others

What the payments were for

  • Food & beverage$64885%
  • Education$11115%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$758 in reported general payments places this provider in the 55th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$139,999
Medicare patients
142
Services billed
1,195

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate15$120,707
AustedoDeutetrabenazine19$115,854
Invega SustennaPaliperidone Palmitate51$115,023
Abilify MaintenaAripiprazole15$39,430
VraylarCariprazine Hcl27$38,294
Aripiprazole426$30,924
FanaptIloperidone11$26,306
RexultiBrexpiprazole15$23,488
Lurasidone Hcl115$21,997
Risperdal ConstaRisperidone Microspheres17$16,612
Paliperidone ErPaliperidone40$15,956
Chlorpromazine Hcl58$12,605
Quetiapine Fumarate955$11,334
BelsomraSuvorexant24$10,560
InvegaPaliperidone13$9,051

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta, Invega$15$140,68681 claims
Neurocrine Biosciences, Inc.Ingrezza$214$120,70715 claims
Teva Pharmaceuticals USA, Inc.Austedo$111$115,85419 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$178$62,91830 claims
AbbVieVraylar$24$38,29427 claims
Vanda Pharmaceuticals Inc.Fanapt$91$26,30611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Tamarac

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →